Osteosarcoma and other tumors of bone.
Although no major advances in local or systemic therapy have been reported, further progress has been made in the identification of genetic alterations and prognostic factors in primary as well as recurrent osteosarcoma. Further reports on the use of a variety of imaging techniques in the quantification of tumor response to neoadjuvant chemotherapy have also appeared. Publications describing high-dose methotrexate pharmacokinetics, the impact of this therapy on patient outcome, and a report of a pilot study evaluating the feasibility of higher dose intensity cisplatin and doxorubicin may lead to new and important randomized clinical trials in the future.
Mertens
W C
WC
London Regional Cancer Centre, Ontario, Canada.
Bramwell
V
V
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009154:Mutation; D012516:Osteosarcoma / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D014054:Tomography; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin; D008727:Methotrexate